Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Endocrinology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Endocrinology Other
    Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight Gain - (DGNews)
    Calcium Protocol Prevents Calcium Deficit After Parathyroidectomy: Presented at ACS - (DGDispatch)
    Ratio of Thyroglobulin to Serum Thyrotropin May Be Tumour Marker for Thyroid Cancer: Presented at AAO-HNSF - (DGDispatch)
    No Relationship Found Between Intraoperative Parathyroid Hormone Levels and Parathyroid Adenoma Mass Size: Presented at AAO-HNSF - (DGDispatch)
    Anaemic Patients With MDS Benefit From Erythropoietin, Myeloid Growth Factor Hormones - (DGNews)

    News archive

     Recent webcasts/CME - Endocrinology Other
    Topics in Male Hypogonadism
    Multidisciplinary Approach to Management of Neuroendocrine Tumors

    Webcasts/CME archive

     Recent cases - Endocrinology Other
      Utility of Follow-Up of 131I-MIBG Scintigraphy to Screen Pheochromocytoma
      Effects of Growth Hormone Reduction in a Patient with Polycystic Ovary Syndrome Complicated with Acromegaly
      Adrenocortical Carcinoma Secreting Cortisol, Androgens and Aldosterone: A Case Report
      Pheochromocytoma in an Accessory Adrenal Gland: A Case Report
      A Novel Heterozygous Mutation of Steroidogenic Factor-1 (SF-1/Ad4BP) Gene (NR5A1) in a 46, XY Disorders of Sex Development (DSD) Patient without Adrenal Failure

      Cases archive
        




      my personal edition > endocrinology other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Adding T3 to Paroxetine Adds No Benefit in Depressed Patients: Presented at ECE

      By Alison Palkhivala

      LYON, FRANCE -- April 28, 2003 -- Adding triiodothyronine (T3) to paroxetine for the treatment of patients with depression does not enhance the efficacy of therapy but does increase side effect incidence.

      In a trial led by Jantien P. Brouwer from the department of endocrinology, Academic Medical Centre, Amsterdam, The Netherlands, 113 patients who met Diagnostic and Statistical Manual - Revision IV criteria for major depressive disorder were randomized to treatment with the selective serotonin reuptake inhibitor (SSRI) paroxetine 30 mg plus placebo, paroxetine 30 mg plus T3 25 mcg (low dose) or paroxetine 30 mg plus T3 50 mcg (high dose) for 8 weeks.

      All participants had a Hamilton Rating Scale for Depression (Ham-D) score of 16 or higher, none had a thyroid or adrenal disorder and none had been treated with an antidepressant in the previous 3 months.

      Overall, 106 patients took at least one dose of the study drug, 50 in the paroxetine alone group, 28 in the paroxetine plus low dose T3 group and 28 in the paroxetine plus high dose T3 group. The trial was 8 weeks long.

      Dr. Brouwer presented the results here on April 28th at the 6th European Congress of Endocrinology.

      The addition of T3 to paroxetine therapy did not influence response or remission rates. Response rate, defined as at least a 50% reduction in Ham-D score, was 46% in all treatment arms. Remission rate, defined as attaining a Ham-D score of 8 or less, was 36% in the paroxetine alone group and 32% in both T3 groups.

      Patients taking T3 had significantly more side effects than those taking paroxetine alone. Most frequent side effects with T3 were sweating, nervousness, palpitations and tremor.

      "My conclusion is short," said Dr. Brouwer. "the addition of T3 to paroxetine is not effective for the treatment of depression."


      [Efficacy Of Triiodothyronine (T3) Addition To Paroxetine In Major Depressive Disorder: A Randomised Clinical Trial. Abstract: O-29.]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send